Business · 19/06/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ROZEREM Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for ROZEREM, a human drug product, as required by law, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →